Zevra Therapeutics Inc
ZVRAHealthcare|Biotechnology|USA
$13.34
-0.59 (-4.23%)
Tangible Book
$3.30
About
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Stock Price
+10.9%(1Y)
Pipeline Summary
5 total trials1
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
Completed: 3ENROLLING_BY_INVITATION: 1Recruiting: 1
Active Trials (1)
Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Pediatric and Adults Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)
NCT06773026Medium-chain Acyl-CoA Dehydrogenase Deficiency
Phase 2Recruiting
Enrollment: 24 participants
BioScore
5.3/10
Watchlist
Ownership
Recent Insider Trades
Thompson RahsaanSELL
2026-06-2234,557 shares @ $12.68
Thompson RahsaanSELL
2026-05-111,794 shares @ $11.3
McFarlane Neil F.SELL
2026-02-0914,625 shares @ $8.56
Sangiovanni Timothy J.SELL
2026-02-033,000 shares @ $9.18
Schafer JoshuaSELL
2026-02-0310,500 shares @ $9.19
Recent News
2026-06-23 17:02:05
2026-06-23 13:50:45
Data last updated: Jul 12, 2026, 07:42 PM